Baird lowered the firm’s price target on NanoString to $10 from $13 and keeps an Outperform rating on the shares. The firm said the reported 2Q results in line with last month’s preview, with consumables driving most of the upside versus their model.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on NSTG:
- NanoString affirms FY23 revenue $175M-$185M, consensus $179.9M
- NanoString reports Q2 EPS (92c), consensus (67c)
- Biotech Alert: Searches spiking for these stocks today
- Court permits NanoString counterclaim in 10x Genomics, Harvard litigation
- NanoString backs FY23 revenue view $175M-$185M, consensus $179.13M